News & Stories

The Hong Kong University of Science and Technology (HKUST) has recently introduced SmartCare – an AI platform developed by HKUST researchers that redefines patient journeys from triage to treatment – in its on-campus clinic. This landmark deployment kicks off a six-month pilot study open to 15,000+ students, faculty, and staff.

The Hong Kong University of Science and Technology (HKUST) and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan Union Hospital) have jointly established the "Collaborative Center for Medical and Engineering Innovation" (the Center), officially unveiled today at HKUST’s campus. The collaboration marks a significant milestone in medical-engineering collaboration between the two institutions, focusing on core areas such as ultrasound, pathology, and radiology. By deeply integrating artificial intelligence (AI) with medical imaging, the center aims to drive medical technology innovation and advance global healthcare progress.

Researchers at The Hong Kong University of Science and Technology (HKUST) have developed a groundbreaking AI technology that reconstructs precise 3D bones and organs models from minimal X-ray images, slashing patients’ radiation exposure by up to 99% compared to CT scans. This innovation not only enhances patient safety but also reduces costs and wait times, with potential applications in surgical planning, real-time imaging, and personalized implants. HKUST team is collaborating with different industry partners, including bone printing company Koln 3D Technology (Medical) Limited (Koln 3D), to implement this technology in public hospitals.

The Hong Kong University of Science and Technology (HKUST) has shone in the second round of Research, Academic and Industry Sectors One-plus (RAISe+) Scheme launched by Innovation and Technology Commission’s (ITC), securing grants for seven teams – the highest number among local institutions.  The seven funded projects encompass a diverse array of innovative research and development efforts. Three projects focus on health and medical innovation, addressing areas spanning diagnostics, medical treatment and gene therapy.  Three others focus on AI chips, semiconductors and their materials, while the remaining one explores novel displays and optoelectronic technology.

The Hong Kong University of Science and Technology (HKUST) and AstraZeneca Hong Kong (AstraZeneca) today announced the signing of a Memorandum of Understanding (MoU) to build on their long-standing partnership, aiming to accelerate research and development (R&D) and drive innovation in the city’s life sciences ecosystem. The signing ceremony was held at the HKUST Unicorn Day 2025, an occasion where entrepreneurs, investors, and industry leaders come together for technological knowledge exchange and collaboration. Witnessed by President of HKUST and the Morningside Professor of Life Science, Prof. Nancy Ip and General Manager of AstraZeneca Hong Kong and Macau Ms. Shan Wu, the MoU was officially signed by Vice-President for Research and Development at HKUST, Prof. Tim Cheng and Head of Medical Affairs, BioPharmaceuticals & Rare Disease of AstraZeneca Hong Kong Mr. Tin Hung Wong.  

The Hong Kong University of Science and Technology (HKUST) has emerged as the top-performing local institution in the second round of the Innovation and Technology Commission’s (ITC) Research, Academic and Industry Sectors One-plus (RAISe+) Scheme, securing funding for seven projects. Spanning health and medical sciences, artificial intelligence (AI) and robotics, advanced manufacturing, and electrical and electronic engineering, these projects underscore HKUST’s leadership in transforming pioneering research into real-world applications.

The Hong Kong University of Science and Technology (HKUST) announced today that  its School of Engineering researchers have developed Mixture of Modality Experts (MOME), a groundbreaking large artificial intelligence (AI) model for non-invasive breast cancer diagnosis. Trained on the China’s largest multiparametric MRI (mpMRI) breast cancer dataset, MOME achieves expert-level accuracy in classifying tumor malignancy, comparable to that of radiologists with five+years of experience. This innovative solution is now undergoing extensive clinical validation across more than ten hospitals and partner institutions, including Shenzhen People’s Hospital, the Guangzhou First Municipal People's Hospital, and Yunnan Cancer Center, to validate its effectiveness and ensure real-world applicability. Harnesses China’s largest mpMRI Dataset

The Hong Kong University of Science and Technology (HKUST) showcased its groundbreaking advancements in medical technology and thought leadership at the 2025 Asia Summit on Global Health (ASGH) today.  As the event’s exclusive Thematic Session and Health Innovation Partner, HKUST highlighted how technology and collaboration can create a more equitable and sustainable healthcare system for hundreds of participants, including policymakers, healthcare experts, industry leaders, start-ups and investors from around the globe.